AstraZeneca’s Imfinzi and Imjudo combinations have been recommended for marketing authorization in the European Union for advanced liver and lung cancers, the company announced. The concurrent positive opinions recommend authorizing Imfinzi in combination with Imjudo for 1st-line treatment of adult patients with advanced or unresectable hepatocellular carcinoma, or HCC; and Imfinzi in combination with Imjudo and platinum-based chemotherapy for the treatment of adult patients with Stage IV non-small cell lung cancer, or NSCLC, AstraZeneca stated.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on AZN:
- AstraZeneca, Daiichi Sankyo announce Enhertu recommended for approval in the EU
- AstraZeneca price target raised to 13,000 GBp from 12,000 GBp at Deutsche Bank
- Merck, AstraZeneca: FDA to extend PDUFA date for sNDA for LYNPARZA combo
- AstraZeneca’s anifrolumab receives FDA orphan designation
- AstraZeneca says Dato-DXd ‘continued to demonstrate encouraging responses’